Clinical Evidence Synthesis Report: Oseltamivir and baloxavir marboxil to treat or prevent influenza A and B

In Switzerland, the antivirals oseltamivir (Tamiflu®) and baloxavir marboxil (baloxavir, Xofluza®) are approved for treatment and prevention of influenza A and B. Switzerland established a stockpile of oseltamivir in 2012. A clinical evidence synthesis regarding the efficacy and safety of oseltamivir was conducted to inform stockpiling decision.

Key Data

Description

On behalf of the Federal Office of Public Health, the Winterthur Institute of Health Economics (WIG) has compiled a clinical evidence synthesis report on the efficacy and safety of the antiviral drugs oseltamivir and baloxavir marboxil. The aim of this report is to support decision-makers in deciding whether the current antiviral stockpile of oseltamivir for influenza pandemic should be maintained, replaced by baloxavir marboxil or dissolved.